Trial sponsors have shared these lung cancer clinical trials that are enrolling participants to help advance lung cancer science. Most medications and treatments currently available are thanks to patients who went through clinical trials to prove the effectiveness and safety of the treatment being studied.

Clinical trials have eligibility requirements to join so that participants remain safe, while having a likelihood of success when it comes to treatment.

If you’re interested in joining one of the clinical trials below, make sure to talk with your doctor and ask if they think it would be helpful for your treatment. Some patients may have additional health problems that could be made worse by treatments used in a clinical trial.

Note: The status of each trial may change with time. Please reach out to the contact listed in each trial opportunity to get the most up-to-date information. 

Available Clinical Trials

NSCLC - ivonescimab + chemotherapy

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Contact:

[email protected]

About the trial:

This is a randomized, Phase 3 global study evaluating ivonescimab plus chemotherapy compared to pembrolizumab plus chemotherapy in patients with metastatic NSCLC who have not received any previous treatment. 

Who can participate?

The study is open to patients with non-squamous and squamous non-small cell lung cancer, regardless of PD-L1 score. HARMONi-3 is evaluating both overall survival (OS) as well as progression-free survival (PFS).

Learn More

SCLC - study drug IDE849

Phase 1/2 multicenter, clinical study of IDE849 in patients with small cell lung cancer (SCLC)

Contact:

[email protected]

About the trial:

The purpose of this study is to assess how safe, tolerable, and effective the study drug, IDE849, is in SCLC. Early studies suggest IDE849 may demonstrate manageable safety and encouraging antitumor activity.

Who can participate?

Patients may be eligible to participate if they have SCLC that has progressed or has returned after previous standard treatment.

Learn More

NSCLC - tumor treating fields

LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer

Contact:

Donald Carlino
[email protected]

About the trial:

This clinical study is evaluating the safety and efficacy of Tumor Treating Fields (TTFields) delivered by the NovoTTF-200T device together with standard immunotherapy, pembrolizumab and platinum-based chemotherapy, compared to pembrolizumab and platinum-based chemotherapy alone for first line treatment of patients with metastatic NSCLC.

Who can participate:

The LUNAR-2 study is intended for patients who have been diagnosed with, but have not been treated for, metastatic non-small cell lung cancer (NSCLC). To be eligible* for this study, you must be at least 18 (22 in the US) years of age, be diagnosed with stage 4 NSCLC, and have not received prior treatments for metastatic NSCLC.

*Not a complete list of eligibility requirements.

Learn More

NSCLC - olvimulogene nanivacirepvec (Olvi-Vec)

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25)

Contact:

Terry Chamberlin, Executive Director, CTO
[email protected]

Tony Yu, SVP, Clinical Development
[email protected]

About the trial:

Promising Immunochemotherapy designed to (i) target and destroy cancer cells, (ii) while helping the immune system recognize and attack tumors and (iii) while re-sensitizing tumors to frontline therapy. Phase 2 randomized trial for participants who have already received frontline standard treatment. 

Who can participate:

For men and women with relapsed or recurrent NSCLC after previous chemotherapy and immunotherapy, no known EGFR, ALK, or ROS1 mutations, and first sign of disease progression. Patients with nonsquamous non-small cell lung cancer or squamous cell lung cancer are eligible. 

Learn More

EGFR+ NSCLC - zipalertinib + chemotherapy

Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection (REZILIENT4)

Contact:

[email protected]

About the trial:

The REZILIENT4 Study is testing the safety and effectiveness of an investigational drug called zipalertinib when given with standard chemotherapy in participants who have nonsquamous non-small cell lung cancer (NSCLC), have had a complete surgical resection (removal) of their tumor, and have certain genetic mutations (abnormal changes in a gene).

Learn More

*These trials are listed for a period of 3 months.